智通财经APP讯，再鼎医药(09688)发布公告，于2025年3月10日(美国东部时间)，公司根据2024年股权激励计划向杜莹博士授出可认购合共25.26万股美国存托股份的购股权，并向杜莹博士授出涉及合共1.06万股美国存托股份的受限制股份单位;以及于2025年3月12日(美国东部时间)，公司根据2024年股权激励计划向4名承授人授出可认购合共24.9万股美国存托股份的购股权，向4名承授人涉及合共8.09万股美国存托股份的受限制股份单位，并向4名承授人授出涉及合共8.09万股美国存托股份的业绩股份单位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.